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appears to be cost-effective in patients receiving chemotherapy
for lung cancer.
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OBJECTIVE: Pharmacoeconomic assessment of erlotinib
(Tarceva) vs best supportive care (BSC) for the treatment of
relapsed NSCLC conducted as part of the Canadian reimburse-
ment submission. METHODS: Analyses were conducted from
the perspective of the Canadian public health care system, and
included cost-effectiveness (CE) of erlotinib vs BSC. The decision
analytic model included three health states (progression-free,
progression and death) with a time horizon of 24–36 months.
The model is a straight forward calculation of the area under the
curve for time spent in the progression-free and progression
health states. The model structure follows the disease pathway
for NSCLC patients and the outcomes captured in the clinical
trials. Cost components included drug acquisition, physician
visits, hospitalizations, laboratory and diagnostic tests/proce-
dures. Deterministic sensitivity analyses were performed.
RESULTS: Incremental CE ratio at 3 years discounted at 5% is
Can $71,018/Life Year Gained vs BSC. During the reimburse-
ment submission process the Common Drug Review (CDR), and
subsequently the Ontario provincial Ministry of Health (MoH)
questioned whether erlotinib should be restricted to certain sub-
groups (i.e. adenocarcinoma histology or HER1/EGFR-positive
groups). However, the pivotal BR.21 erlotinib trial showed an
overall survival beneﬁt in an unselected patient population (56%
HER1/EGFR status unknown). As all BR.21 molecular subgroup
analyses were exploratory and underpowered, tests of interac-
tion did not identify a molecular subgroup with a better survival
when treated with erlotinib that was statistically signiﬁcant. In
particular HER1/EGFR protein expression was not found to
impact on survival in the BR.21 trial. Based on these data, the
CDR and MoH in Ontario subsequently conﬁrmed subgroup-
speciﬁc CE analyses were not required. CONCLUSIONS:
Erlotinib received positive recommendations from the CDR.
Ontario, British Columbia, Quebec, Nova Scotia and New-
foundland are provinces currently reimbursing erlotinib from
their provincial drug plans.
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OBJECTIVES: The aim of the study was to evaluate the cost-
effectiveness of erlotinib compared to docetaxel and pemetrexed
after failure of previous treatment for stage IIIB/IV NSCLC in
Poland. METHODS: Markov health-state model was used to
estimate the direct medical costs and outcomes (overall survival
and QALY) of treating NSCLC in the Polish setting. This model
incorporates clinical data from published pivotal trials and local
data of health care resource utilisation and unit cost. The per-
spective of health care payers and time horizon of 3 years was
considered. Probabilistic sensitivity analysis was used to address
uncertainty. RESULTS: There were no differences between
treatments with respect to overall survival (0.83 year) and the
number of QALY—0.26 (erlotinib and pemetrexed) and 0.24
(docetaxel). The expected average costs/patient treated with
erlotinib, docetaxel and pemetrexed were: 51,743, 78,039,
92,385 PLN (1 EURO = 3.8 PLN in 2006). Hence erlotinib dom-
inates both docetaxel and pemetrexed (at least equal efﬁcacy and
lower cost). The average cost saving associated with erlotinib
treatment vs. docetaxel and pemetrexed was 26,295 and 40,642
PLN/patient, respectively. Probabilistic sensitivity analysis con-
ﬁrmed results of the deterministic analysis. In a 100% simula-
tion erlotinib remained a dominant treatment strategy in
comparison to docetaxel and pemetrexed. CONCLUSIONS:
Given the results of the analysis erlotinib as 2nd/3rd line agent
in the treatment of patients with advanced NSCLC may be rec-
ommended as ﬁrst-choice treatment because of its cost-saving
potential in comparison to docetaxel and pemetrexed.
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OBJECTIVES: The oral ﬂuoropyrimidine capecitabine is as
effective but better tolerated than i.v. 5-FU/LV as ﬁrst-line treat-
ment in patients with metastatic colorectal cancer. Costs associ-
ated with the administration route could vary widely according
to national rules and medical practice. We compared costs 
and outcomes of capecitabine, Mayo Clinic and de Gramont 
regimens as adjuvant treatment for stage III colon cancer.
METHODS: We assessed the cost-effectiveness of the three reg-
imens using the French third-party payer perspective, time
horizon and efﬁcacy/safety data (adjusted for indirect compar-
isons) from two published clinical trials [Twelves et al. N Engl J
Med 2005; Andre et al. J Clin Oncol 2003]. Medical resource
use and related-cost of chemotherapy and side-effect treatment
were estimated from the clinical trials and expert opinion. Only
grade 3/4 adverse events were considered when comparing
capecitabine to the de Gramont regimen. We applied French
standard costs to resources consumed and evaluated cost-
effectiveness using relapse-free survival as an efﬁcacy indicator.
One-way sensitivity analyses were performed varying the cost
estimates for each treatment. RESULTS: Capecitabine-treated
patients had a mean life duration increase without treatment
failure of 1.3 months vs. Mayo (35 months vs. 33.7 months). De
Gramont was considered as effective as Mayo. In the base-case
analysis, capecitabine is less costly than the Mayo Clinic
(€3961.04 vs. €10,985.66) and de Gramont (€3697.05 vs.
€7266.06) regimens. Capecitabine appeared to be dominant,
more effective and less costly than either of the 5-FU regimens.
In the sensitivity analyses, capecitabine remained dominant
except for the minimum costs scenario vs. de Gramont. In this
case, the cost-effectiveness ratio was estimated at €4511.36 per
year without relapse. CONCLUSIONS: As adjuvant treatment
for colon cancer, capecitabine decreases medical resources con-
sumed, mainly in hospitals. Its approval in this setting is expected
to bring cost savings and better outcomes.
